Session ID: 2025-07-05:10a1c60e64bc8d9a3e64a294 Player Element ID: Vf442f6fa_a10e_431e_bef8_08df4b04895f_6374239823112 ...

Session ID: 2025-07-01:c3d96494478f7322ba15e67b Player Element ID: Vd5cd1b33_dfb7_4cb6_a47a_a289603d2ac9_6374240200112 ...

TORONTO--(BUSINESS WIRE)--Breast Cancer Canada proudly celebrates the federal government’s response to the External Expert Review (EER) of the Canadian Task Force on Preventive Health Care, and ...

In the study, more than 3,200 patients with advanced ER-positive, HER2-negative breast cancer were tested with Guardant360 CDx every two or three months. If the test picked up on an emerging ESR1 ...

Yet, there’s a growing trend that can’t be ignored: a disturbing rise in breast cancer diagnoses among young women. In fact, for women between the ages of 20 and 49, breast cancer is the ...

Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) combined with Perjeta (pertuzumab) as first-line treatment improved progression-free survival (PFS) versus standard care for patients with ...

More information: Komal L. Jhaveri et al, Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2501796 ...

Groundbreaking new treatment for aggressive breast cancer has 100% survival rate By Reda Wigle Published May 30, 2025, 9:18 a.m. ET ...

HR-positive, HER2-negative breast cancer is already the most common subtype of breast cancer, comprising 70% of the breast cancers in the U.S., according to ASCO.

Per Susan G. Komen, people diagnosed with stage 1 breast cancer have a 98 to 100 percent five-year survival rate; stage 2 comes with a 90 to 99 percent survival rate.

Key Takeaways The APHINITY study confirmed significant overall survival benefits of a Perjeta-based regimen in HER2-positive early-stage breast cancer, especially for lymph node-positive patients. Ten ...

The advent of next-generation antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), has transformed our understanding of human epidermal growth factor receptor 2 (HER2) ...